MARKET

BMRA

BMRA

Biomerica Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.150
+0.090
+2.94%
After Hours: 3.220 +0.07 +2.22% 16:06 05/18 EDT
OPEN
3.140
PREV CLOSE
3.060
HIGH
3.210
LOW
2.980
VOLUME
36.85K
TURNOVER
45.73K
52 WEEK HIGH
7.38
52 WEEK LOW
2.650
MARKET CAP
40.48M
P/E (TTM)
-7.4556
1D
5D
1M
3M
1Y
5Y
36 of the Best Ideas Companies to Present at the Spring into Action - Best Ideas Investor Conference on May 16th - 20th, 2022
RALEIGH, NC / ACCESSWIRE / May 16, 2022 / The Spring into Action- Best Ideas Virtual Investor Conference will take place on May 16th \- 20th, 2022, where 36 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual webcast to a global ...
ACCESSWIRE · 2d ago
Biomerica gets EU's CE mark for its diagnostic test to detect H. pylori bacteria
Biomerica (NASDAQ:BMRA) on Thursday said it got the European Commission's CE Mark for its hp+detect diagnostic test that detects the bacteria Helicobacter pylori. BMRA stock -0.2% to $2.78 in premarket trade. The CE
Seekingalpha · 6d ago
Biomerica Announces CE Mark for Its H. pylori Diagnostic Test, hp+detect™
- Attaining CE Mark is a major step toward commercialization – - World Health Organization (WHO) lists H. pylori among the 16 antibiotic-resistant bacteria that pose the greatest threat to human health and designated H. pylori as a Class 1 carcinogen, mean...
GlobeNewswire · 6d ago
Biomerica Says H Pylori Diagnostic Test Receives CE Mark
MT Newswires · 6d ago
Biomerica stock rises on filing with FDA to market bacteria detection test
Biomerica (NASDAQ:BMRA) submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for hp+detect test that detects the presence of Helicobacter pylori (H. pylori) bacteria. The company said that over
Seekingalpha · 04/26 13:15
BRIEF-Biomerica Reports FDA Submission For Test to Detect H. pylori
reuters.com · 04/26 12:21
Biomerica Reports FDA Submission For Test To Detect Helicobacter Pylori
Gastric cancer is the third most common cause of cancer related death in the world and over 80% of gastric cancers are attributed to H. pylori bacterial infection H. pylori infection is also a major cause of peptic
Benzinga · 04/26 12:19
Biomerica Announces FDA Submission For a Test to Detect Helicobacter pylori (H. pylori), a Bacteria That Infects Approximately 35% of the US Population
Gastric cancer is the third most common cause of cancer related death in the world and over 80% of gastric cancers are attributed to H. pylori bacterial infection H. pylori infection is also a major cause of peptic ulcers IRVINE, Calif., April 26, 2022 (GL...
GlobeNewswire · 04/26 12:19
More
No Data
Learn about the latest financial forecast of BMRA. Analyze the recent business situations of Biomerica Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

100.00%Strong Buy
0.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average BMRA stock price target is 13.00 with a high estimate of 13.00 and a low estimate of 13.00.
High13.00
Average13.00
Low13.00
Current 3.150
EPS
Actual
Estimate
-0.10-0.07-0.05-0.02
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Q4 2022
Institutional Holdings
Institutions: 41
Institutional Holdings: 3.47M
% Owned: 26.97%
Shares Outstanding: 12.85M
TypeInstitutionsShares
Increased
5
83.90K
New
8
140.17K
Decreased
3
85.18K
Sold Out
4
174.50K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-2.73%
Healthcare Equipment & Supplies
-2.35%
Key Executives
Chairman/Director/Chief Executive Officer
Zackary Irani
Vice Chairman/Executive Director/Secretary/Director
Allen Barbieri
Chief Financial Officer/Treasurer
Steven Sloan
Independent Director
Catherine Coste
Independent Director
Jane Emerson
Independent Director
Mark Sirgo
No Data
No Data
About BMRA
Biomerica, Inc., (Biomerica) is a biomedical technology company. The Company develops, patents, manufactures and markets diagnostic and therapeutic products for the early detection and monitoring of chronic diseases and other medical conditions. The Company's diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications, by measuring or detecting the of specific bacteria, hormones, antibodies, antigens, or other substances, in a patient body, stools, or blood, saliva or nasal fluid. The Company is engaged in research and development of disruptive, patented diagnostic guided therapy (DGT) products to treat gastrointestinal diseases, such as irritable bowel syndrome (IBS), and other inflammatory diseases.

Webull offers kinds of Biomerica, Inc. stock information, including NASDAQ:BMRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BMRA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BMRA stock methods without spending real money on the virtual paper trading platform.